Literature DB >> 15302839

Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice.

Lucia Mazzolai1, Michel A Duchosal, Martine Korber, Karima Bouzourene, Jean François Aubert, Hiroyuki Hao, Veronique Vallet, Hans-R Brunner, Jürg Nussberger, Giulio Gabbiani, Daniel Hayoz.   

Abstract

Rupture of vulnerable plaques is the main cause of acute cardiovascular events. However, mechanisms responsible for transforming a stable into a vulnerable plaque remain elusive. Angiotensin II, a key regulator of blood pressure homeostasis, has a potential role in atherosclerosis. To study the contribution of angiotensin II in plaque vulnerability, we generated hypertensive hypercholesterolemic ApoE-/- mice with either normal or endogenously increased angiotensin II production (renovascular hypertension models). Hypertensive high angiotensin II ApoE-/- mice developed unstable plaques, whereas in hypertensive normal angiotensin II ApoE-/- mice plaques showed a stable phenotype. Vulnerable plaques from high angiotensin II ApoE-/- mice had thinner fibrous cap (P<0.01), larger lipid core (P<0.01), and increased macrophage content (P<0.01) than even more hypertensive but normal angiotensin II ApoE-/- mice. Moreover, in mice with high angiotensin II, a skewed T helper type 1-like phenotype was observed. Splenocytes from high angiotensin II ApoE-/- mice produced significantly higher amounts of interferon (IFN)-gamma than those from ApoE-/- mice with normal angiotensin II; secretion of IL4 and IL10 was not different. In addition, we provide evidence for a direct stimulating effect of angiotensin II on lymphocyte IFN-gamma production. These findings suggest a new mechanism in plaque vulnerability demonstrating that angiotensin II, within the context of hypertension and hypercholesterolemia, independently from its hemodynamic effect behaves as a local modulator promoting the induction of vulnerable plaques probably via a T helper switch.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302839     DOI: 10.1161/01.HYP.0000140269.55873.7b

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  43 in total

Review 1.  Dual opposing roles of adaptive immunity in hypertension.

Authors:  Noureddine Idris-Khodja; Muhammad Oneeb Rehman Mian; Pierre Paradis; Ernesto L Schiffrin
Journal:  Eur Heart J       Date:  2014-03-30       Impact factor: 29.983

2.  Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary.

Authors:  John Hallenbeck; Gregory Del Zoppo; Tom Jacobs; Antoine Hakim; Stephen Goldman; Ursula Utz; Ahmed Hasan
Journal:  Stroke       Date:  2006-11-02       Impact factor: 7.914

Review 3.  Dysregulation of T cell subsets in the pathogenesis of hypertension.

Authors:  Songcang Chen; Devendra K Agrawal
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

4.  Valsartan Attenuates Atherosclerosis via Upregulating the Th2 Immune Response in Prolonged Angiotensin II-Treated ApoE(-/-) Mice.

Authors:  Kai Meng; Qiutang Zeng; Qinghua Lu; Yingzhong Lin; Bangwei Wu; Kunwu Yu; Zhaoqiang Dong; Jianwei Zhang; Meng Chai; Yuyang Liu; Qingwei Ji; Yujie Zhou
Journal:  Mol Med       Date:  2015-02-09       Impact factor: 6.354

5.  Differential roles of endothelin-1 in angiotensin II-induced atherosclerosis and aortic aneurysms in apolipoprotein E-null mice.

Authors:  Renée S Suen; Sarah N Rampersad; Duncan J Stewart; David W Courtman
Journal:  Am J Pathol       Date:  2011-06-29       Impact factor: 4.307

6.  Comparison of 99mTc-annexin A5 with 18F-FDG for the detection of atherosclerosis in ApoE-/- mice.

Authors:  Yan Zhao; Yuji Kuge; Songji Zhao; Koichi Morita; Masayuki Inubushi; H William Strauss; Francis G Blankenberg; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-17       Impact factor: 9.236

7.  Cathepsin G activity lowers plasma LDL and reduces atherosclerosis.

Authors:  Jing Wang; Sara Sjöberg; Ting-Ting Tang; Katariina Oörni; Wenxue Wu; Conglin Liu; Blandine Secco; Viviane Tia; Galina K Sukhova; Cleverson Fernandes; Adam Lesner; Petri T Kovanen; Peter Libby; Xiang Cheng; Guo-Ping Shi
Journal:  Biochim Biophys Acta       Date:  2014-08-01

Review 8.  Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.

Authors:  Shuaibo Huang; Nikolaos G Frangogiannis
Journal:  Br J Pharmacol       Date:  2018-03-04       Impact factor: 8.739

9.  Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity.

Authors:  Michael Platten; Sawsan Youssef; Eun Mi Hur; Peggy P Ho; May H Han; Tobias V Lanz; Lori K Phillips; Matthew J Goldstein; Roopa Bhat; Cedric S Raine; Raymond A Sobel; Lawrence Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-19       Impact factor: 11.205

Review 10.  Darkness at the end of the tunnel: poststenotic kidney injury.

Authors:  Alfonso Eirin; Lilach O Lerman
Journal:  Physiology (Bethesda)       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.